文献速递认知障碍与痴呆

高剂量与标准剂量流感疫苗接种后阿尔茨海默痴呆风险比较

Risk of Alzheimer Dementia After High-Dose vs Standard-Dose Influenza Vaccination.
PubMed 文献 · Neurology · 2026-04-01

该回顾性队列研究基于美国医保索赔数据库,纳入2014—2019年≥65岁、无认知障碍指征的成人,比较高剂量与标准剂量灭活流感疫苗接种后新发阿尔茨海默痴呆风险。采用序贯嵌套试验模拟与逆概率加权,发现高剂量组在接种后1—25个月AD风险显著更低(最小NNT=185.2,25个月时),女性风险降低持续时间长于男性。证据等级为Class II。

要点

  • ≥65岁成人接种高剂量较标准剂量流感疫苗与AD风险降低相关。
  • 接种后1—25个月风险显著降低,25个月时最小NNT=185.2。
  • 女性风险降低持续1—13个月(最小NNT=416.7),男性仅17—24个月意向性分析显著。

核心结论

  • 在≥65岁美国医保索赔数据库人群中,高剂量流感疫苗较标准剂量与AD风险降低相关。

研究设计与样本

  • 回顾性队列研究,数据来自2014—2019年IQVIA PharMetrics Plus for Academics美国医保索赔数据库。
  • 高剂量组120,775人(185,183人-试验;平均年龄74.4岁,SD 5.5;57.3%女性)。
  • 标准剂量组44,022人(53,918人-试验;平均年龄73.0岁,SD 6.1;56.4%女性)。
  • 采用序贯嵌套试验模拟、逆概率加权与自举法获取95%CI,随访至接种后3年。

主要发现

  • 高剂量组在接种后1—25个月AD风险显著低于标准剂量组,25个月时最小NNT=185.2。
  • 女性风险降低持续至1—13个月,最小NNT=416.7。
  • 男性风险降低仅17—24个月在意向性分析中显著,最小NNT=232.6。

关键数值与推荐

  • AD定义采用ICD编码及AD药物发放(抗胆碱酯酶抑制剂、美金刚)。
  • 效应估计包括风险差、NNT、风险比,95%CI通过自举法获得。

临床怎么用

  • 对≥65岁无认知障碍成人,选择高剂量而非标准剂量流感疫苗可能附带AD风险降低的获益。
  • 女性可能从高剂量疫苗的AD风险降低中获益持续时间更长。

局限性

  • 随访时间≤3年。
  • 缺乏社会人口学、生活方式、生物标志物及死亡数据。
  • 尚需研究明确观察到的差异反映流感感染保护还是非感染相关机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Previous studies, including large cohort analyses comparing vaccinated and unvaccinated adults, suggest that routine immunizations such as inactivated influenza vaccines (IIVs) may reduce Alzheimer dementia (AD) risk. Whether AD risk differs after high-dose IIV (H-IIV) vs standard-dose IIV (S-IIV) remains unexamined. We hypothesized that AD risk would be lower among adults ≥65 years after H-IIV compared with S-IIV. METHODS: This retrospective cohort study analyzed data spanning 2014-2019 from IQVIA PharMetrics Plus for Academics, a US health care claims database. Eligible participants were ≥65 years with ≥2 years of continuous medical and pharmaceutical coverage and no previous diagnostic or pharmacotherapeutic indicators of cognitive impairment. Vaccinations were identified by name and Current Procedural Terminology codes. Participants were followed for up to 3 years postvaccination. Incident AD was defined using International Classification of Diseases codes and AD medication dispenses (anticholinesterase inhibitors, memantine). We emulated a target trial using sequential nested trials to align eligibility, treatment assignment, and time-zero with vaccination dates, preventing immortal time bias. Inverse probability weighting adjusted for measured confounding, emulated randomization, and mitigated selection bias. Effects were estimated as risk difference, number needed to treat (NNT), risk ratio; 95% CIs were obtained via bootstrapping. Secondary analyses examined potential effect modifiers such as sex. RESULTS: The H-IIV group included 120,775 unique participants (185,183 person-trials; mean age 74.4 years, SD 5.5; 57.3% female), and the S-IIV group included 44,022 participants (53,918 person-trials; mean age 73.0, SD 6.1; 56.4% female). H-IIV was associated with significantly lower AD risk during months 1-25 postvaccination (minimum NNT = 185.2 at 25 months). After sex stratification, risk reduction persisted longer among women (months 1-13, minimum NNT = 416.7) than men (months 17-24, significant only in intention-to-treat analysis, minimum NNT = 232.6). DISCUSSION: High-dose influenza vaccination is associated with reduced AD risk compared with standard-dose vaccination in adults ≥65 years, with a stronger effect among women. Significant study limitations included duration of follow-up (≤3 years) and lack of sociodemographic, lifestyle, biomarker, and mortality data. Further research is needed to clarify whether the observed difference reflects protection against influenza infection or non-infection-related mechanisms. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that treatment with H-IIV vs S-IIV was associated with decreased incident dementia in individuals ≥65 years of age captured in this US health care claims database.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Bukhbinder AS, Ling Y, Jhin L, et al. Risk of Alzheimer Dementia After High-Dose vs Standard-Dose Influenza Vaccination. Neurology. 2026. PMID: 41921123. doi:10.1212/WNL.0000000000214782

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。